Memorial Sloan-Kettering Cancer Center: Rockville Centre

Rockville Centre, New York 11570

0 studies enrolling now · 12 studies all time

What they study most

Adenocarcinoma of the Prostate, Bladder Cancer, Breast Cancer, Cancer of the Prostate, Castration-resistant Prostate Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Head and Neck Cancer, Hormone Sensitive Prostate Cancer, Hormone-resistant Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer

Studies at this site

• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer — Completed
• RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer — Running, not enrolling
• Cisplatin vs Paclitaxel for Triple Negative Breast Cancer — Completed
• Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer — Status unconfirmed
• Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer — Completed
• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer — Status unconfirmed
• Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer — Completed
• Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery — Completed
• A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations — Stopped early
• S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct — Completed
• Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer — Stopped early